Article
Dr. Jack Cush reviews the news and journal reports from RheumNow.com - and the top 5 reasons to attend RheumNow Live 2026, which is one week away.
All News
Article
Retraction of rheumatology studies is not uncommon; a recent analysis shows retractions have risen substantially.
Article
Dr. Cush addresses the management of difficult-to-treat rheumatoid arthritis (D2TRA).
Article
A recent study examines trends in rheumatoid arthritis (RA)-related mortality among U.S. postmenopausal women (aged 55 and older). They found RA mortality rates have declined, yet disparities in who is most affected persist, especially for white women, and those over 85 yrs of age.
Dr. John Cush
Tweet
NEJM - Baker’s Cyst
A 63-year-old woman with psoriatic arthritis presented with a 9-month history of pain in the left knee. A nontender, palpable mass was present in the left popliteal fossa, which had a “speech bubble” shape on ultrasonography. https://t.co/7wBnkDoUaX https://t.co/m0AhRnDc4c
Dr. John Cush
Tweet
Consensus on Managing Vertebral Fractures in Advanced CKD
A coalition of leading international experts has released the first comprehensive Consensus Statement on the Management of Vertebral Fractures in Chronic Kidney Disease (CKD) Stages G4–G5D. The statement highlights a https://t.co/gilX13EaUi
Dr. John Cush
Tweet
IXCHIQ - a live-attenuated chikungunya virus vaccine: 10-30% have mild-moderate adverse effects, w/ headache, fatigue, & myalgia. <3% have severe AEs. Rare reports of encephalitis in elderly post Ixchiq, due to type I IFN-neutralizing autoantibodies (same w/ yellow-fever Vax) https://t.co/3VlZCd4sGc
Dr. John Cush
Tweet
2026 SPARTAN Annual Meeting (May 14-16; Toronto) is now accepting abstract submissions! A premier mtg brings together cutting-edge researchers and teachers in spondyloarthritis (SpA). Submit your abstracts by Feb 1st!! https://t.co/IBXEkSxpDy https://t.co/cS7exDUc9H
Dr. John Cush
Tweet
Longitudinal study of 1761 US military service pre- & post-deployment. The prevalence of fibromyalgia in Males/Females was 2.%/2% (sames as civilians) but post-deploy incr to 8%/11% (P < 0.001). PTSD incr from 21% /18% to 23%/26%. PTSD predeployment lead to a 3 fold risk of FM. https://t.co/XTjuhjx0zd
Dr. John Cush
Tweet
DARWIN study ADHD med use among children and adults in Europe (Belgium, Germany, Netherlands, Spain, UK) more than doubled betw 2010 to 2023. IN UK use went up 20X in females, 15X males. (Ed. note: ADHD meds-->poor sleep-->fibromyalgia-->MSK pains) https://t.co/KlvUF1vhhj https://t.co/yEWXwM0WBL
Dr. John Cush
Tweet
Emergencies, Independence & Hemorrhage (1.23.2026)
Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.
https://t.co/l4iMADwA1A https://t.co/YB4mnb8Xlu
Aurelie Najm
Tweet
Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, and real-world insights with Drs. Jack Cush, Arthur Kavanaugh, and a powerhouse faculty. Register: https://t.co/zh0aBDMfoP
@RheumNow
Dr. John Cush
Tweet
What Is Restless Legs Syndrome? JAMA Patient Education handout. https://t.co/fCqArVxrSu https://t.co/WjFNWyr9Q2
Dr. John Cush
Tweet
Evaluation of pts w/ muscle weakness and elevated muscle enzymes https://t.co/faTWMscUzz https://t.co/Dcx8m4Ny7Y
Dr. John Cush
Tweet
“We will remember not the words of our enemies, but the silence of our friends.”
- Martin Luther King, Jr.
Dr. John Cush
Tweet
Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/1Yn3OXXEH6 https://t.co/HmQiYFSQMU
Dr. John Cush
Tweet
ANAs and Autoantibodies
https://t.co/AANvCKeAl0 https://t.co/SSPUxMEuLh
Dr. John Cush
Tweet
Review of Restless Legs Syndrome
JAMA has published a full review of RLS - restless leg syndrome - a frequent, but often unrecognized, cause of poor sleep and the resultant hazards of insomnia.
https://t.co/lPSMH3v7xS https://t.co/lbSfeNrfLz
Dr. John Cush
Tweet
Acupuncture in SpA metanalysis of 35 RCTs (2,591 AS pts) showed statistically significant improvements BASDAI score, BASFI score, ASDAS, VAS score, CRP level, and ESR level. Findings imited by high heterogeneity & the lack of large-scale, high-quality RCTs. https://t.co/gznAiNo0k4
Dr. John Cush
Tweet
Retrospective real-world study of 87 Behcets dz pts & inital Rx w/ IFX (n 45) or ADA (n 42) (2020 to 2025) & >60% were on AZA. Complete remission achieved in 76% (IFX) vs 79% (ADA) initially, & 89% vs 77% last visit. Same Rx retention but more relapses w/ IFX (38% v 17%) https://t.co/6FiuYe0GI9
